Company description

Apellis Pharmaceuticals Inc. (APLS) is a biopharmaceutical company focused on developing innovative treatments for patients with autoimmune and inflammatory diseases. The company's main focus is on developing targeted therapies for complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), autoimmune hemolytic anemia (AIHA), and geographic atrophy (GA). Apellis has developed a proprietary platform, called the CELSTAT System, which utilizes monoclonal antibodies to inhibit specific proteins in the complement cascade, a key component in the body's immune response. This technology has shown promising results in clinical trials, with potential to revolutionize treatment options for patients suffering from debilitating conditions. In addition to their breakthrough therapies, Apellis also has a strong commitment to patient advocacy and collaboration with healthcare professionals. The company has a global presence, with headquarters in Waltham, Massachusetts and research facilities in Switzerland and the Netherlands. With a strong management team and a growing pipeline of potential treatments, Apellis is poised to make a significant impact in the medical community and improve the lives of patients worldwide.